BDC-4182 Reports Q4 Revenue of $2.5M, Exceeding Expectations
Reports Q4 revenue $2.5M, consensus $857,250. "BDC-4182 is the first of our next-generation Boltbody ISACs to enter the clinic, and we saw a clear difference versus our first-gen ISACs in terms of immune response from the very first patient treated," said Willie Quinn, president and CEO. "The ISAC mechanism is radically different from ADCs and T cell engagers, and we believe that demonstrating anti-tumor activity with BDC-4182 will unlock an entirely new approach to treating cancer. We continue to enroll patients with gastric and gastroesophageal cancers in the Phase 1 dose-escalation trial and remain on track to report initial data in the third quarter of 2026."
Trade with 70% Backtested Accuracy
Analyst Views on BOLT
About BOLT
About the author
Bolt Biotherapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Bolt Biotherapeutics reported a Q4 GAAP EPS of -$3.84, beating market expectations by $1.57, indicating improvements in cost control and operational efficiency.
- Revenue Growth: The company achieved revenue of $2.5 million in Q4, exceeding expectations by $1.64 million, suggesting increasing market acceptance of its products, which could lay the groundwork for future growth.
- Market Reaction: Although still in a loss position, the better-than-expected earnings report may boost investor confidence, potentially leading to a positive impact on stock prices and attracting more institutional investors.
- Future Outlook: The financial performance of Bolt Biotherapeutics demonstrates its potential in the biopharmaceutical sector, and if it can continue to improve its financial situation, it will help the company secure a more advantageous position in a competitive market.
Bolt Announces Q3 2025 Financial Results and Updates on Oncology Pipeline Advancements
Company Overview: Bolt Biotherapeutics, Inc. reported its Q3 2025 financial results, highlighting its focus on developing immunotherapies for cancer through its proprietary Boltbody ISAC platform, which includes two clinical-stage candidates, BDC-3042 and BDC-4182.
Clinical Trials Update: BDC-3042, targeting tumor-associated macrophages, has shown early signs of immune activation in a Phase 1 study, while BDC-4182 is being evaluated for gastric and gastroesophageal cancers, with initial data expected in Q3 2026.
Financial Performance: The company reported a narrowed net loss of $7.1 million for Q3 2025, a significant improvement from the previous year, attributed to reduced R&D and G&A costs following a corporate restructuring.
Stock Performance: Bolt's stock has fluctuated between $4.42 and $13 over the past year, closing at $4.69 recently, with a slight increase in overnight trading.
HC Wainwright & Co. Initiates Coverage on Bolt Biotherapeutics with a Buy Rating and Sets Price Target at $7
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community and Exclusivity: Joining Benzinga Pro connects traders with over 10,000 members and provides access to exclusive stories and insights from Benzinga reporters.
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Clinical Study Results: BDC-3042, a novel immunotherapy developed by Bolt Biotherapeutics, demonstrated a favorable safety profile and biological activity in a Phase 1 clinical trial, with no serious adverse events reported and signs of anti-tumor activity in patients with various cancers.
Future Development Plans: The company is seeking partnerships to accelerate the development of BDC-3042, which targets dectin-2 on tumor-associated macrophages, and aims to explore its potential in combination with other therapies for improved patient outcomes.
HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeuticsto Neutral
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Clinical Trials Update: Bolt Biotherapeutics is set to begin a clinical trial for BDC-4182, targeting gastric cancer, in the second quarter of 2025, while the Phase 1 trial for BDC-3042 has been fully enrolled with no dose-limiting toxicities reported.
Financial Overview: As of December 31, 2024, Bolt Biotherapeutics has a cash balance of $70.2 million, expected to fund operations and key milestones through mid-2026, despite reporting a net loss of $63.1 million for the year.
Bolt Biotherapeutics Q4 Earnings Beat Expectations
- Earnings Highlights: Bolt Biotherapeutics reported a Q4 GAAP EPS of -$3.84, beating market expectations by $1.57, indicating improvements in cost control and operational efficiency.
- Revenue Growth: The company achieved revenue of $2.5 million in Q4, exceeding expectations by $1.64 million, suggesting increasing market acceptance of its products, which could lay the groundwork for future growth.
- Market Reaction: Although still in a loss position, the better-than-expected earnings report may boost investor confidence, potentially leading to a positive impact on stock prices and attracting more institutional investors.
- Future Outlook: The financial performance of Bolt Biotherapeutics demonstrates its potential in the biopharmaceutical sector, and if it can continue to improve its financial situation, it will help the company secure a more advantageous position in a competitive market.
Bolt Announces Q3 2025 Financial Results and Updates on Oncology Pipeline Advancements
Company Overview: Bolt Biotherapeutics, Inc. reported its Q3 2025 financial results, highlighting its focus on developing immunotherapies for cancer through its proprietary Boltbody ISAC platform, which includes two clinical-stage candidates, BDC-3042 and BDC-4182.
Clinical Trials Update: BDC-3042, targeting tumor-associated macrophages, has shown early signs of immune activation in a Phase 1 study, while BDC-4182 is being evaluated for gastric and gastroesophageal cancers, with initial data expected in Q3 2026.
Financial Performance: The company reported a narrowed net loss of $7.1 million for Q3 2025, a significant improvement from the previous year, attributed to reduced R&D and G&A costs following a corporate restructuring.
Stock Performance: Bolt's stock has fluctuated between $4.42 and $13 over the past year, closing at $4.69 recently, with a slight increase in overnight trading.
HC Wainwright & Co. Initiates Coverage on Bolt Biotherapeutics with a Buy Rating and Sets Price Target at $7
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.
Community and Exclusivity: Joining Benzinga Pro connects traders with over 10,000 members and provides access to exclusive stories and insights from Benzinga reporters.
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Clinical Study Results: BDC-3042, a novel immunotherapy developed by Bolt Biotherapeutics, demonstrated a favorable safety profile and biological activity in a Phase 1 clinical trial, with no serious adverse events reported and signs of anti-tumor activity in patients with various cancers.
Future Development Plans: The company is seeking partnerships to accelerate the development of BDC-3042, which targets dectin-2 on tumor-associated macrophages, and aims to explore its potential in combination with other therapies for improved patient outcomes.
HC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeuticsto Neutral
Real-time Market Intelligence: Benzinga Pro offers the fastest and most accurate stock market alerts, helping traders stay informed and make winning trades daily.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, gaining access to exclusive stories and insights from Benzinga reporters.
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Clinical Trials Update: Bolt Biotherapeutics is set to begin a clinical trial for BDC-4182, targeting gastric cancer, in the second quarter of 2025, while the Phase 1 trial for BDC-3042 has been fully enrolled with no dose-limiting toxicities reported.
Financial Overview: As of December 31, 2024, Bolt Biotherapeutics has a cash balance of $70.2 million, expected to fund operations and key milestones through mid-2026, despite reporting a net loss of $63.1 million for the year.
